The REDUCE-IT trial of cardiovascular outcomes with prescription fish oil pills (Vascepa) will continue as planned after the scheduled interim analysis suggested no problems, manufacturer Amarin announced, noting that it had set the bar high for stopping due to efficacy to try to get the most robust results.